SCHEMBL3365486

SCHEMBL3365486

CSc1cc(-c2ccc(Oc3ccccc3)cc2)nn1C(=O)Nc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
HPGD P15428 2/20 0.42
SCN4A P35499 1/20 0.42
MAPK14 Q16539 1/20 0.41
FAAH O00519 3/20 0.41
MAPT P10636 1/20 0.41
SCN9A Q15858 1/20 0.41
BTK Q06187 2/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 2/20 0.40
NPC1 O15118 2/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40
MCL1 Q07820 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PGR P06401 1/20 0.39
PDGFRB P09619 2/20 0.39
PNLIP P16233 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3367014 0.93 MAPT (0.47) SMN1; SMN2FAAHMAPTALDH1A1LMNA
SCHEMBL3552650 0.89 MAPT (0.45) SMN1; SMN2HPGDFAAHMAPTALDH1A1
SCHEMBL3367196 0.83 SCN4A (0.54) SCN4ASCN9ABTKALDH1A1NPC1
SCHEMBL3370342 0.82 KMT2A (0.45) SMN1; SMN2HPGDSCN4AMAPTKDM4E
SCHEMBL1225270 0.78 KMT2A (0.50) SMN1; SMN2HPGDSCN4AMAPTALDH1A1
SCHEMBL3366888 0.78 HPGD (0.47) SMN1; SMN2HPGDFAAHMAPTBTK
SCHEMBL11746060 0.76 MAPT (0.40) SMN1; SMN2HPGDMAPTKDM4EALDH1A1
SCHEMBL427247 0.69 SCN4A (0.64) SMN1; SMN2HPGDSCN4AMAPK14ALDH1A1
SCHEMBL23657744 0.67 ENPP3 (0.46) SMN1; SMN2HPGDMAPK14FAAHMAPT
SCHEMBL24878631 0.66 HPGD (0.67) SMN1; SMN2HPGDMAPTALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1173169-B1 ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF EURO CELTIQUE SA (LU) 2010-05-12 EP disclosed
US-6737418-B2 CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS EURO-CELTIQUE S.A. (LU) 2004-05-18 US disclosed
US-20030069292-A1 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof EURO-CELTIQUE S.A. 2003-04-10 US disclosed
US-6414011-B1 CENTRAL NERVOUS SYSTEM DISORDERS EURO-CELTIQUE S.A. (LU) 2002-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069292-A1 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof GRIK5, GRIN3A, GRIK3 SMN1; SMN2 13/4885HPGD 1751/4885SCN4A 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.